Journey Medical (DERM) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 24, 2025, with voting open until June 23, 2025, 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by June 10, 2025.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of six directors: Lindsay A. Rosenwald, M.D., Claude Maraoui, Neil Herskowitz, Justin Smith, Miranda Toledano, and Michael Pearce.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Approval of the Fourth Amended and Restated Certificate of Incorporation, including officer exculpation provisions.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and all proposals.
Latest events from Journey Medical
- EMROSI's launch drove 10% revenue growth, margin gains, and improved profitability in 2025.DERM
Q4 202525 Mar 2026 - Q2 revenue $14.9M, positive EBITDA, DFD-29 FDA review ongoing, but going concern risks remain.DERM
Q2 20241 Feb 2026 - FDA approves Emrosi for rosacea, launching in early 2025 with proven superiority to Oracea.DERM
FDA Announcement17 Jan 2026 - Dermatology-focused pharma seeks $150M via flexible offerings amid ongoing losses and dilution risk.DERM
Registration Filing15 Jan 2026 - Emrosi FDA approval and launch set the stage for growth after a pivotal 2024.DERM
Q4 202426 Dec 2025 - Emrosi launches in April with best-in-class efficacy, targeting rapid adoption and broad coverage.DERM
Status Update3 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve officer exculpation amendment.DERM
Proxy Filing2 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and approve officer exculpation amendment.DERM
Proxy Filing2 Dec 2025 - Emrosi's launch drove $2.1M in Q1 revenue, margin gains, and optimism despite ongoing risks.DERM
Q1 202526 Nov 2025